Clinical significance of erythropoietin levels in renal carcinoma.
The bioassay using the polythemic mice demonstrated persistent erythropoietin (Ep) activity in 24 renal carcinoma patients. Eight patients without clinical evidence of renal carcinoma had Ep levels that were slightly higher than those of controls, suggesting the possibility of occult disease. Increased levels of Ep were noted in 5 patients with other genitourinary carcinomas. This selective study reaffirms the value of Ep as a biologic marker in some renal cell cancers, and occasionally in other genitourinary tumors.
D000368:Aged; D000818:Animals; D001681:Biological Assay; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000473:pathology / Q000628:therapy; D004921:Erythropoietin / Q000097:blood*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008875:Middle Aged; D011086:Polycythemia / Q000097:blood; D014565:Urogenital Neoplasms / Q000097:blood
D004921:Erythropoietin